A clinical trial to investigate the comparability of relief from methacholine-induced bronchoconstriction with CHF1535 100/6 μg NEXThaler® versus CHF1535 100/6 μg pMDI in asthmatic patients

Femme et Homme

| Pays :
| Organes :
| Spécialités :

Extrait

To demonstrate the non-inferiority of CHF1535 100/6 μg NEXThaler® versus CHF1535 100/6 μg pMDI on the onset of relief from methacholine-induced bronchospasm, in terms of pulmonary function [change in FEV1 (L) from baseline, i.e. post-diluent, to 5 min after study drug inhalation] in asthmatic patients on low-medium doses of ICS or ICS plus LABA fixed or free combination.

Critère d'inclusion

Asthma

Liens

euctr